Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gritstone Oncology Inc (GRTS)
NASDAQ:GRTS
Gritstone Oncology (GRTS) Stock Price & Analysis
747 Followers
GRTS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.67 - $3.33
Previous Close$0.75
Volume402.46K
Average Volume (3M)2.99M
Market Cap
$81.07M
Enterprise Value$106.91M
Total Cash (Recent Filing)$79.29M
Total Debt (Recent Filing)$104.78M
Price to Earnings (P/E)-0.6
Beta1.66
Next Earnings
Aug 07, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding108,569,374
10 Day Avg. Volume2,821,393
30 Day Avg. Volume2,993,292
Standard Deviation0.52
R-Squared0.00441
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.59
Price to Sales (P/S)4.98
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.54
Enterprise Value/Gross Profit6.54
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$5.00Price Target Upside569.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Gritstone Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsGritstone's GRANITE study shows promising early results, particularly for high-risk patients, signaling potential for positive impacts on progression-free survival and patient outcomes.
Financial StabilityThe company has a strong financial position, with enough cash to fund its operations well into the future, ensuring continued progress in its projects and stability for investors.
Regulatory MilestonesWith a potential end-of-Phase 2 meeting with the FDA on the horizon, Gritstone is poised for critical regulatory advancements that could significantly boost investor confidence.
Bears Say
Financial PerformanceGritstone reported lower than expected grant and licensing revenues and a higher net loss per share than consensus estimates.
Operational SetbacksPhase 2 COVID study for the next-generation vaccine CORAL has been delayed, which required some short-term adjustments and workforce reduction.
Stock ValuationPrice Target trimmed from $8 to $6, factoring in increased spend and related costs.
---
Ownership Overview
21.38% Insiders
7.80% Mutual Funds
22.48% Other Institutional Investors
48.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRTS FAQ
What was Gritstone Oncology Inc’s price range in the past 12 months?
Gritstone Oncology Inc lowest stock price was $0.67 and its highest was $3.33 in the past 12 months.
What is Gritstone Oncology Inc’s market cap?
Currently, no data Available
When is Gritstone Oncology Inc’s upcoming earnings report date?
Gritstone Oncology Inc’s upcoming earnings report date is Aug 07, 2024 which is in 83 days.
How were Gritstone Oncology Inc’s earnings last quarter?
Gritstone Oncology Inc released its earnings results on May 09, 2024. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.319 by -$0.021.
Is Gritstone Oncology Inc overvalued?
According to Wall Street analysts Gritstone Oncology Inc’s price is currently Undervalued.
Does Gritstone Oncology Inc pay dividends?
Gritstone Oncology Inc does not currently pay dividends.
What is Gritstone Oncology Inc’s EPS estimate?
Gritstone Oncology Inc’s EPS estimate is -$0.28.
How many shares outstanding does Gritstone Oncology Inc have?
Gritstone Oncology Inc has 108,569,374 shares outstanding.
What happened to Gritstone Oncology Inc’s price movement after its last earnings report?
Gritstone Oncology Inc reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.319. Following the earnings report the stock price went down -19.588%.
Which hedge fund is a major shareholder of Gritstone Oncology Inc?
Among the largest hedge funds holding Gritstone Oncology Inc’s share is Versant Venture Management, LLC. It holds Gritstone Oncology Inc’s shares valued at 7M.
---
Gritstone Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (569.61% Upside)
$5.00 (569.61% Upside)
Blogger Sentiment
Bullish
GRTS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 87.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.68%
12-Months-Change
Fundamentals
Return on Equity
-187.15%
Trailing 12-Months
Asset Growth
-34.65%
Trailing 12-Months
Company Description
Gritstone Oncology Inc
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.
---
GRTS Company Deck
---
GRTS Earnings Call
Q1 2024
0:00 / 0:00
---
GRTS Stock 12 Month Forecast
Average Price Target
$5.00
▲(569.61% Upside)
Technical Analysis
Corvus Pharmaceuticals
―
Voyager Therapeutics
―
Rocket Pharmaceuticals
―
Adaptimmune Therapeutics
―
Best Analysts Covering GRTS
1 Year
1 Year Success Rate
5/22 ratings generated profit
1 Year Average Return
-14.97%
reiterated a buy rating 4 days ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 22.73% of your transactions generating a profit, with an average return of -14.97% per trade.
---